Aflibercept Intravitreous Injection

Aflibercept intraocular injection solution is a vascular endothelial growth factor inhibitor, and its main clinical indications are neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Aflibercept is a therapeutic protein drug, a fusion protein produced by Chinese hamster ovary (CHO) K1 cells through recombinant DNA technology. The fusion protein is a homodimeric glycoprotein formed by the fusion of the extracellular domain of human vascular endothelial growth factor receptor (VEGFR) (i.e., VEGFR1 Ig2 region and VEGFR2 Ig3 region) with the Fc domain of human IgG1; it is a vascular endothelial growth factor inhibitor, a soluble decoy receptor that can bind to vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF), and can inhibit the binding and activation of endogenous VEGF receptors with VEGF-A and PlGF.